Graves' disease in children and adolescents in Iceland

被引:0
作者
Porsson, Porbergur Atli [1 ]
Bjarnason, Ragnar [1 ,2 ]
Jonasdottir, Soffia Gudrun [3 ]
Jonsdottir, Berglind [2 ]
机构
[1] Laeknadeild Haskola Isl, Reykjavik, Iceland
[2] Landspitala, Barnaspitala Hringsins, Reykjavik, Iceland
[3] Domus Med, Reykjavik, Iceland
来源
LAEKNABLADID | 2022年 / 108卷 / 03期
关键词
Graves' disease'; pediatric; treatment; Iceland; AMERICAN THYROID ASSOCIATION; AUTOIMMUNE HYPERTHYROIDISM; PREPUBERTAL CHILDREN; INCREASING INCIDENCE; THYROTOXICOSIS; PREDICTORS; MANAGEMENT; REMISSION; GUIDELINES; CHILDHOOD;
D O I
10.17992/lbl.2022.03.680
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: Graves' disease is an autoimmune disease in which autoantibodies cause an increase in the production of thyroid hormones, and is the most common cause of thyrotoxicosis in children. Symptoms in children are often more obscure than in adults. The aim of the study is to assess the incidence of Graves' disease in children and adolescents in Iceland over the span of two decades (2001-2021), and furthermore to investigate if the incidence rate has increased, as well as to describe treatment options and disease recurrence. MATERIAL/METHODS: This retrospective descriptive study included all children diagnosed with Graves' disease in the years 2001-2021 in Iceland. Information was obtained from the Directorate of Health's drug database and from ICD-10 diagnoses at Landspitali - The National University Hospital. RESULTS: In total, 57 children and adolescents were diagnosed with Graves', the overall incidence rate was 3.5/100,000 person-years. Gender ratio was 1:2.7 (male : female) and the mean age at diagnosis was 13.6 for boys and 13.9 years for girls. Of those 12 individuals currently receiving drug therapy (21.8%), four patients have had disease relapse. Thirteen patients reached an euthyroid state with medication (23.7%), 25 received treatment with radioactive iodine (45.5%) and 5 underwent surgery (9.1%). Boys were more likely to relapse. Disease recurrence was 31.8%. CONCLUSION: The incidence of Graves' disease did not increase during the study period. The disease was more common in girls, although the gender ratio was lower than expected. Antithyroid drugs were the first choice in treatment and radioactive iodine was the most common permanent treatment option. Disease recurrence was common. A possible relationship between the duration of the original drug therapy and disease recurrence should be investigated.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 50 条
  • [41] Important considerations when choosing pharmacotherapy for Graves' disease in children
    Krol, Aleksandra
    Krajewska, Jolanta
    Jarzab, Barbara
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (14) : 1675 - 1677
  • [42] The association between methimazole tapering and intractable Graves' disease in children
    Kim, Sung Eun
    Park, Su Jin
    Sim, Soo Yeun
    Kim, Seul Ki
    Ahn, Moon Bae
    Kim, Shin Hee
    Cho, Won Kyoung
    Cho, Kyoung Soon
    Jung, Min Ho
    Suh, Byung-Kyu
    PEDIATRICS INTERNATIONAL, 2024, 66 (01)
  • [43] A Belgian single centre outcome study of radioiodine treatment in adolescents with Graves' disease
    Chielens, Laura
    Nauwynck, Elise
    Bourgeois, Sophie
    Staels, Willem
    Vanbesien, Jesse
    Gies, Inge
    Ernst, Caroline
    Everaert, Hendrik
    De Schepper, Jean
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [44] Graves' disease in children with Down syndrome
    Cebeci, Ayse Nurcan
    Schempp, Vera
    Foertsch, Katharina
    Gohlke, Bettina
    Marx, Michaela
    Doerr, Helmuth-Guenther
    Woelfle, Joachim
    ENDOCRINE CONNECTIONS, 2024, 13 (06)
  • [45] Controversies in the management of Graves' disease in children
    Rivkees, S. A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2016, 39 (11) : 1247 - 1257
  • [46] Approach to the Pediatric Patient with Graves' Disease: When Is Definitive Therapy Warranted?
    Bauer, Andrew J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) : 580 - 588
  • [47] Treatment and outcome of patients with Graves' disease and metastatic differentiated thyroid cancer
    Besic, Nikola
    Vidergar-Kralj, Barbara
    RADIOLOGY AND ONCOLOGY, 2023, 57 (03) : 380 - 388
  • [48] Graves' disease: developments in first-line antithyroid drugs in the young
    Lane, Laura C.
    Cheetham, Tim
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2020, 15 (02) : 59 - 69
  • [49] Antithyroid drug therapy for Graves' disease
    Shin, Soo Myoung
    Yi, Ka Hee
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2021, 64 (10): : 690 - 698
  • [50] Effect of liver dysfunction on outcome of radioactive iodine therapy for Graves' disease
    Ze, Yuyang
    Shao, Fei
    Feng, Xuefeng
    Shen, Shanmei
    Bi, Yan
    Zhu, Dalong
    Zhang, Xiaowen
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)